Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]HRS9531 in Healthy Male Subjects
NCT06855147Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS9531 in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Maximum concentration up to 64 days, Time to reach maximum concentration up to 64 days and 5 more. Started Apr 2025; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06855147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855147.